New Blood Test Identifies Alzheimer’s Memory Loss With 90% Accuracy
Human brains are destined to fail. Determining whether memory decline is a sign of more than typical aging requires technology that isn’t always available, leaving specialists to rely solely on their experience and judgment to spot signs of dementia
However, scientists have now confirmed that an already clinically available blood test can supplement current diagnostic methods where expensive scans and spinal fluid samples aren’t options, and it appears to deliver extremely high accuracy as well.
Researchers at Lund University in Sweden led a team of scientists in evaluating whether a combination of protein ratios found in human serum can accurately detect Alzheimer’s pathology in patients.
Some 55 million people around the globe live with dementia, mostly in the form of Alzheimer’s disease.
While the processes at work involve a complicated mix of genetic and environmental factors, one thing all individuals with Alzheimer’s have in common is a steady loss of key neurons associated with a marked rise in abnormal proteins.
Those two proteins – beta-amyloid and tau – clump and tangle in ways that either directly damage cells or inflict a degree of assault by other immunological processes.
General practitioners and specialists often use CT scans that reveal this degradation of brain tissue in association with cognitive tests and self-reported symptoms to gauge whether a patient is likely to have Alzheimer’s disease.
Yet even in a best-case scenario with a full range of diagnostic tools at their disposal, both primary and secondary care providers often fail to make the right call.
“Primary care doctors’ accuracy in identifying Alzheimer’s disease was 61 per cent, while specialist physicians were correct 73 per cent of the time,” says Lund University neurologist Sebastian Palmqvist.
“This underscores the lack of good, cost-effective diagnostic tools, particularly in primary care, and indicates the potential improvement in diagnosis with the adoption of this blood test in healthcare settings.”
Numerous studies conducted in recent years have highlighted the potential role of plasma protein measures in the diagnosis of Alzheimer’s disease, specifically comparative ratios of the ‘normal’ and aberrant forms of beta-amyloid and tau.
While similar tests have been carried out on spinal fluid, a commercially available blood test would be far less invasive, less painful, and quicker to carry out in a regular clinic.
To confirm whether the blood test is as reliable, Palmqvist and his team recruited 1213 patients who were being evaluated for Alzheimer’s by their family doctor or a specialist in Sweden some time between February 2020 and January 2024.
Around two-thirds of the patients had been classified as having either subjective cognitive decline or mild cognitive impairment, while the remaining third had already received a diagnosis of dementia based on a mix of clinical and cognitive tests.
In addition to the blood test, most patients also received a lumbar puncture for spinal fluid. The few who couldn’t underwent a radionuclide-tagged PET scan instead to assess abnormal aggregations of proteins in the brain.
Comparing the results, both forms of assessment fared just as well, predicting Alzheimer’s with a 90 percent accuracy.
The convenience of a blood test means more patients can receive an accurate diagnosis sooner, allowing them to receive the healthcare they require without delay.
“The test is already available in the USA and is likely to become available in many other countries soon,” says senior researcher Oskar Hansson, a neurologist at Lund University.
“Initially, it will mainly be used in specialist memory clinics, and it may take approximately one to two years to implement guidelines and training in primary care.”
This research was published in JAMA.
See more here sciencealert.com
Header image: News Medical
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.
VOWG
| #
Then the enforced suicide starts. “Science” looks less like science every day.
Reply
Wisenox
| #
“Alzheimer’s have in common is a steady loss of key neurons associated with a marked rise in abnormal proteins.”
EMF causes the same symptoms through calcium signaling. Ghz wavelengths induce mechanical stress on the endoplasmic reticulum, and it increases the selectivity of calcium ions in the voltage gate. This creates a calcium pump, which is usually a second messenger. The first part of the pathway, involving jnk/p38 is bypassed and the usual cellular safeguards are inhibited.
The calcium signals the mitochondria to produce ATP, which in turn phosphorylates the MEK/ERK2 pathway. This leads to caspase 3, and possibly calpain, which will sever the c-terminus of cell wall pores and tau proteins. The taus will then ‘clump’, which is termed ‘tau aggregation’.
The ATP will also cause the phosphorylation of AChE, which is responsible for regulating acetylcholine in ion channels and synapse depolarization. The AChE is now unusable, permanently, and the person will have ion channel loading and poor mental ability. The lack of choline, from the inhibition of AChE will prevent the replenishment of the phosphatyidl choline protective sheath around neurons and they will decay. Thus, Alzheimers.
They can ‘detect’ Alzheimers, but it remains questionable if they actually want to prevent it.
Reply
Saeed Qureshi
| #
Remember, we are still struggling with COVID-19 tests, like PCR, developed by the so-called “scientists” and ended up with fake viruses, pandemics, and vaccines. May Almighty protect us from these “scientists” who are doing test development without knowing the science of it.
https://bioanalyticx.com/doctors-science-requires-audit-and-accountability/
Reply
Richard
| #
I remember my father was classed with early dementia . As long as I could get him to drink more liquids those early signs seem to disappear …. Weird that !
Reply
Jerry Krause
| #
Hi Readers,
What was the point of the blood test? Is the point to prevent efforts to treat those of us with poor memories, that decline as we get older, that the cause is probably not Alzheimer’s? I have no idea if there are treatments to prevent or slow the progress of Alzheimer’s, but both of my parents lived past 90. My mother was 13 years younger than mu father. My father died because he began to have tiny strokes which prevented him from swallowing liquids or food. With the doctor’s approval let him die naturally, instead of prolonging his life with medical treatments. Just to prevent any possible pain.
My mother retired from life when my father died and she lived more than 13 years as a vegetable.to die at about 96. She was heathy but I guess we could have stopped fielding her and let her slowly starve to death. VOWG, what would have been your solution?
Have a good day
Reply